Introducing Radiotherapy in Metastatic Merkel Cell Carcinoma Patients with Limited Progression on Avelumab: An Effective Step against Primary and Secondary Immune Resistance?

Purpose: To investigate the ability of radiotherapy (RT) to prolong progression-free survival (PFS) and to report treatment-related toxicities among oligoprogressive metastatic Merkel cell carcinoma (mMCC) patients on avelumab. Methods: We retrospectively collected clinical data on mMCC patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferini, Gianluca, Zagardo, Valentina, Critelli, Paola, Santacaterina, Anna, Sava, Serena, Harikar, Mandara Muralidhar, Venkataram, Tejas, Umana, Giuseppe Emmanuele, Viola, Anna, Valenti, Vito, Forte, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224079/
https://www.ncbi.nlm.nih.gov/pubmed/37241012
http://dx.doi.org/10.3390/jpm13050841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224079/
https://www.ncbi.nlm.nih.gov/pubmed/37241012
http://dx.doi.org/10.3390/jpm13050841

Ejemplares similares